JCR Pharmaceuticals (4552) · InitiativeAdvanced
Establishment of AlliedCel Co., Ltd., a joint venture with Sysmex
First written in FY2023-Q3. 1 of 2 entries say "Advanced", first in FY2023. Latest entry: FY2023.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Establishment of a regenerative medicine R&D joint venture with SysmexA theme 2 companies write about · 0 as a headwind · 2 as a tailwind
1 other company's latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2023AdvancedAnnual report
「Established AlliedCel Co., Ltd. in Chuo-ku, Kobe, jointly with Sysmex Corporation, to conduct research and development of regenerative medicine products; currently an equity-method affiliate」
The role of AlliedCel Co., Ltd., a joint venture with Sysmex Corporation, was defined more specifically as a company established to conduct research and development of regenerative medicine products. The Company disclosed a 50.0% voting-rights ownership ratio and classified it as an equity-method affiliate. - FY2023-Q3First statedAnnual report
「During the third quarter consolidated accounting period, Mycenax Biotech Inc. was acquired and AlliedCel Co., Ltd., a joint venture with Sysmex Corporation, was newly established. Both were included in the scope of application of the equity method.」
The Company disclosed for the first time that AlliedCel Co., Ltd., a joint venture with Sysmex Corporation, had been newly established and included as an equity-method affiliate. The text does not describe the joint venture's business purpose or specific activities.